Navigation Links
MiMedx Group Partners With Affirmative Solutions
Date:9/21/2011

KENNESAW, Ga., Sept. 21, 2011 /PRNewswire/ -- MiMedx Group, Inc.  (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it has partnered with Affirmative Solutions, a national, leading distributor of spine, biologic and other medical products and devices to the U.S. Veteran's Administration ("VA") and Department of Defense ("DOD") facilities.

A nationally established company, Affirmative Solutions is certified as a Service Disabled Veteran-Owned Small Business (SDVOSB) that is dedicated to meeting the needs of Medical Treatment Facilities ("MTF") with a widely diverse range of quality medical and commercial products.  Affirmative Solutions markets, sells and serves as a financial liaison to MTFs operated by the VA and the DOD, as well as, commercial healthcare facilities throughout the United States. Affirmative Solutions currently distributes products and devices to over 100 major VA, DOD and commercial facilities across the country.

Through the distribution agreement, the MiMedx wound care offering, Epifix®, can now be offered to all the MTFs serviced by Affirmative Solutions, who through its SDVOSB status, is a preferred supplier to all its government accounts. MiMedx currently markets four sizes of Epifix®, and all four sizes are included in the agreement with negotiated pricing established at competitive rates.  

MiMedx Chairman and CEO, Parker H. "Pete" Petit, commented, "This agreement is a significant step in MiMedx offering its products and tissues into the VA and DOD by partnering with a well-established distributor in this space. MiMedx will have access to all of the MTFs served by Affirmative Solutions, including those operated by the VA and DOD, plus select commercial MTFs. A hallmark of Affirmative Solutions is their high quality standards for customer service, and we are very pleased to have a distribution partner that shares our passion for service excellence," added Petit.

"We are very excited about our relationship with Affirmative Solutions," said Bill Taylor, MiMedx President and COO. "They have done an extraordinary job in growing their business model. With the significant market potential of our tissue offerings, it is critical that we align with an organization such as Affirmative Solutions that can grow and expand to meet the fast-paced demands of the market."    

About the Company

MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane.  "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix™ and CollaFix™, and our tissue technologies, AmnioFix® and EpiFix®. Our tissue technologies, processed from the human amniotic membrane, utilize our proprietary Purion® process that was developed by our wholly-owned subsidiary, Surgical Biologics, to produce a safe, effective and minimally manipulated implant. Surgical Biologics is the leading supplier of amniotic tissue, having supplied over 35,000 implants to date to distributors and OEMs for application in the Ophthalmic, Orthopedics, Spine, Wound Care and Dental sectors of healthcare.

Safe Harbor Statement

This press release includes statements that look forward in time or that express management's beliefs, expectations or hopes.  Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements include, but are not limited to the potential impact of the Company's agreement with Affirmative Solutions in establishing the MiMedx products and tissues in the VA and DOD; the impact of the Company's access to the MTFs on the demand for the Company's products and tissues; the market potential of the Company's tissue offerings; and the ability of Affirmative Solutions to grow and expand to meet the demands of the market. These statements are based on current information and belief, and are not guarantees of future performance.  Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include that the anticipated demand for the Company's products and tissues as a result of the agreement with Affirmative Solutions and the Company's access to the MTFs does not materialize; that the market opportunities created by the agreement are below expectations; that the market potential for the Company's products and tissues is less than anticipated; that Affirmative Solutions may not be able to grow and expand as anticipated; and the risk factors detailed from time to time in the Company's periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended December 31, 2010, and its most recent Form 10-Q. By making these forward-looking statements, the Company does not undertake to update them in any manner except as may be required by the Company's disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws.


'/>"/>
SOURCE MiMedx Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MiMedx Group Receives FDA Clearance to Market Its HydroFix™ Ortho Shield™ Device
2. MiMedx Announces Launch of AmnioFix™ Nerve Wrap
3. MiMedx to Attend International Society for the Advancement of Spine Surgery Annual Meeting
4. MiMedx Group, Inc. Announces Release Date for First Quarter Results
5. MiMedx Completes Acquisition of Surgical Biologics
6. MiMedx Receives Additional CE Certification for Its HydroFix™ Technology
7. MiMedx Announces Agreement to Acquire Surgical Biologics
8. MiMedx Group, Inc. Announces Release Date for Second Quarter Results
9. MiMedx Group Announces Addition of Sales Director for Europe
10. MiMedx Group Announces CE Mark for the HydroFix(TM) Spine Shield
11. MiMedx Group Announces Launch of its Paradis Vaso Shield(TM) Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Research ... Pharma News Issue 52" report to their offering. ... in influenza treatment creates a favourable commercial environment for MedImmune ... growing patient base that will serve to drive considerable growth ... vaccine would serve to cap sales considerably, but development is ...
(Date:6/23/2016)... Ill. and INDIANAPOLIS , ... students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is ... 2016 scholarship winners, announced today online at www.diabetesscholars.org ... let type 1 diabetes stand in the way of ... has supported the Foundation,s scholarship program since 2012, and ...
(Date:6/23/2016)... 23, 2016  Guerbet announced today that it has ... Horizon Award . One of 12 suppliers ... for its support of Premier members through exceptional local ... and commitment to lower costs. ... of our outstanding customer service from Premier," says ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ... raise to $12 an hour by 2020 and then adjusting it yearly to increase at ... the minimum wage, assure the wage floor does not erode again, and make future increases ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... for human induced pluripotent stem (iPS) cells and other difficult to transfect cells, ... Cloning Medium. The PluriQ™ G9™ Gene Editing System is a complete ...
(Date:6/24/2016)... ... 2016 , ... Southern Illinois University School of Dental Medicine ... State Dental Society (ISDS) Foundation’s Mission of Mercy (MOM). They will host a ... , They expect to treat approximately 2,000 patients from Illinois, Missouri, ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Blood Supply Foundation, a not-for-profit organization responsible for clinical transfusion research programs and ... enrollment for the Pathogen Reduction Evaluation and Predictive Analytical Rating Score (PREPAReS) study. ...
Breaking Medicine News(10 mins):